Ixabepilone in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

This study has been completed.

Study NCT00033618 Information provided by Eastern Cooperative Oncology Group

First Received: April 9, 2002 Last Updated: January 27, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	January 2007 (Final data collection date for primary outcome measure)

Publications:

Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol. 2008 Feb 21; [Epub ahead of print]

Burtness B, Goldwasser MA, Axelrod R, et al.: A randomized phase II study of BMS-247550 (ixabepilone) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. [Abstract] J Clin Oncol 24 (Suppl 18): A-5532, 288s, 2006.

Burtness B, Manola J, Argiris A, et al.: Randomized phase II study of BMS-247550 (NSC 710428) given daily X 5 days or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: E2301. [Abstract] European Journal of Cancer Supplements 4 (12): A-632, 190, 2006.